|
Aug 12
|
Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Jun 18
|
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
|
|
May 11
|
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Q1 2024 Relmada Therapeutics Inc Earnings Call
|
|
May 9
|
Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
|
|
May 8
|
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
|
May 6
|
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
|
|
Mar 20
|
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
|
|
Mar 20
|
Q4 2023 Relmada Therapeutics Inc Earnings Call
|
|
Mar 19
|
Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results
|
|
Mar 19
|
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
|
|
Mar 12
|
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
|
|
Mar 5
|
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
|
|
Mar 4
|
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
|
|
Feb 1
|
Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares
|
|
Feb 1
|
Relmada Therapeutics CEO & Director Acquires 69% More Stock
|
|
Jan 5
|
Health Care Roundup: Market Talk
|
|
Jan 4
|
Relmada Therapeutics Provides Corporate Update
|
|
Dec 29
|
11 Best Psychedelic Stocks to Buy in 2024
|
|
Oct 6
|
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
|